{
    "2020-03-11": [
        [
            {
                "time": "2020-03-16",
                "original_text": "Dow Jones Makes Bear Market Correction On Coronavirus Fears; Will 'Stay At Home' Stocks Win Big In 2020?",
                "features": {
                    "keywords": [
                        "Dow Jones",
                        "Bear Market",
                        "Coronavirus",
                        "Stay At Home"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "general market"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2020-02-28",
                "original_text": "Aduro's (ADRO) Earnings & Revenues Miss Estimates in Q4",
                "features": {
                    "keywords": [
                        "Aduro",
                        "Earnings",
                        "Revenues",
                        "Miss Estimates"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2020-03-12",
                "original_text": "Dow Jones Slammed 1,284 Points On Coronavirus Fears; Will 'Stay At Home' Stocks Win Big In 2020?",
                "features": {
                    "keywords": [
                        "Dow Jones",
                        "Slammed",
                        "Coronavirus",
                        "Stay At Home"
                    ],
                    "sentiment_score": -0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "general market"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2020-03-11",
                "original_text": "Dow Jones Slammed 1,151 Points On Coronavirus Fears; Will 'Stay At Home' Stocks Win Big In 2020?",
                "features": {
                    "keywords": [
                        "Dow Jones",
                        "Slammed",
                        "Coronavirus",
                        "Stay At Home"
                    ],
                    "sentiment_score": -0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "general market"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2020-04-15",
                "original_text": "Lilly to Participate in New Model Designed to Make Insulins More Affordable for Seniors in Medicare Part D",
                "features": {
                    "keywords": [
                        "Lilly",
                        "Insulins",
                        "Affordable",
                        "Medicare"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2020-02-10",
                "original_text": "Pharma M&A Has Slowed to a Crawl",
                "features": {
                    "keywords": [
                        "Pharma",
                        "M&A",
                        "Slowed"
                    ],
                    "sentiment_score": -0.5,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2020-03-05",
                "original_text": "Eli Lilly Gets Analyst Praise",
                "features": {
                    "keywords": [
                        "Eli Lilly",
                        "Analyst Praise"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2020-01-15",
                "original_text": "US govt aims at high insulin prices with plan for $35 copay in Medicare",
                "features": {
                    "keywords": [
                        "US govt",
                        "Insulin Prices",
                        "Medicare"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare policy"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            }
        ]
    ]
}